Alkhotani Amal, Alrishi Nouf, Alharthi Meshari, Alzahrani Waleed
Department of Medicine, Umm Al Qura University.
Department of neurology, King Abdulla Medical City, Makkah.
Medicine (Baltimore). 2020 Nov 25;99(48):e23316. doi: 10.1097/MD.0000000000023316.
Atrial fibrillation is the most common cardiac arrhythmia. Anticoagulation therapy effectively reduces systemic embolization in patients with non-valvular atrial fibrillation, but intracranial hemorrhage (ICH) is a major possible complication. This study assessed the real-time rate of rivaroxaban-associated ICH in Saudi patients.We retrospectively reviewed patients with ICH during rivaroxaban therapy, assessing clinical features and outcomes.Four cases out of 690 patients were identified in total, indicating an incidence of ICH during rivaroxaban therapy of 0.58%. Hematoma expansion developed in 1 case. Three out of four patients were discharged after ICH, and 1 patient died.The incidence of rivaroxaban-related ICH was similar to that previously reported, and the risk of hematoma expansion was low. Further studies are required to validate our results.
心房颤动是最常见的心律失常。抗凝治疗可有效降低非瓣膜性心房颤动患者的全身性栓塞，但颅内出血（ICH）是一种主要的可能并发症。本研究评估了沙特患者中利伐沙班相关颅内出血的实时发生率。我们回顾性分析了利伐沙班治疗期间发生颅内出血的患者，评估其临床特征和转归。总共690例患者中发现4例，表明利伐沙班治疗期间颅内出血的发生率为0.58%。1例出现血肿扩大。4例患者中有3例在颅内出血后出院，1例死亡。利伐沙班相关颅内出血的发生率与先前报道相似，血肿扩大风险较低。需要进一步研究来验证我们的结果。
